Food and Drug Administration (FDA) has cleared Biomea’s IND application to begin a Phase I/Ib trial of BMF-219, a selective, covalent menin inhibitor in patients with unresectable, locally advanced, or metastatic NSCLC, CRC, and PDAC with an activating KRAS mutation. “We are very excited...
Currently, direct sequencing, namely, polymerase chain reaction (PCR) followed by dideoxy sequencing, is still the gold standard method for detecting mutations. This method is able to detect all mutations in the region of interest, but it requires a high allele frequency of mutation (10–30%) ...
has proven to be a successful strategy to achieve positive clinical impacts in human cancer. Elucidating the details of the KRAS protein’s lifecycle is therefore of significant interest, not only in understanding mechanisms of oncogene biology, but also in informing therapeutic strategies towards direc...
在结直肠癌循环肿瘤细胞中KRAS和PIK3CA的突变以及EGFR异质性的研究 Studyintroduction •美国国家癌症综合治疗联盟（NCCN）《结直肠癌临床实践指南》(2019)明确指出：(1)所有转移性结直肠癌患者都应检测KRAS基因状态；(2)只有KRAS野生型患者才建议接受EGFR抑制剂（如爱必妥和帕尼单抗）治疗。NCCN《非小细胞肺癌临床实践...
interactions within the G-domain of KRAS that can be triggered either by an oncogenic mutation such as A146T or modification at the N-terminus (lack of either the iMet or N-acetylation). Inside the crystal, the fully open switch I conformation has minimal interaction with neighboring ...
Rescue of the KRAS Mutation by Genome Editing To validate whether the phenotypes described above were attributable to the specific KRAS genotype, we attempted to generate “gene-corrected” wild-type iPSCs from a G13C/WT clone. For genome editing, we used the CRISPR/Cas9 system for one G13...
"Patients who have undergone surgery for pancreatic cancer are still at risk for relapse of the disease, even after they finish chemotherapy. This is especially true for patients who are positive for circulating tumor DNA (ctDNA), which puts them at a higher risk for relapse," said principal ...
2.The method of claim 1, wherein said subject has been previously determined or is simultaneously determined to have a cancer comprising the oncogenic Kras mutation. 3.The method of claim 2, wherein said Kras mutation is selected from the group consisting of KrasG12D, KrasG12V, KrasG13D,...
Genotype by Colon tissue KRAS 35C KRAS 38A ACTB Strands ACTB Strands mutation mutation Sample ID sequencing histology Strands* Strands* (35C)** (38A)** HEX FAM Call 054DAA G34T ADENOMA — 6,785 17,998 22,346 0% 30% Positive 036DAA G35A CANCER 641 1,061 4,890 5,953 13% 18% ...
HRAS G12C or NRAS G12C mutation in a subject in need thereof, the method comprising: determining if the subject has a KRAS, HRAS or NRAS G12C mutation; and if the subject is determined to have the KRAS, HRAS or NRAS G12C mutation, then administering to the subject a therapeutically ...